Alexion Pharma International Operations LTD

General

Total Cases1

Active Cases--

Patents--

CourtsD. Delaware

TypeOperating Company

Elite Ratings

--

--

--

--

Ratings

Experience

Grade

Trend

DCT

--

--

--

PTAB

--

--

--

CAFC

--

--

--

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered	Case	Description
09/03/24	Alexion Pharmaceuticals Inc v. Samsung Bioepis Co Ltd 1:24-CV-00005 ( D. DE )	Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (jaa) (Entered: 09/03/2024)
09/03/24	Alexion Pharmaceuticals Inc v. Samsung Bioepis Co Ltd 1:24-CV-00005 ( D. DE )	SO ORDERED, re 79 Stipulation and Order of Dismissal Without Prejudice. ***Civil Case Terminated.. Signed by Judge Gregory B. Williams on 9/3/24. (jaa) (Entered: 09/03/2024)
08/30/24	Alexion Pharmaceuticals Inc v. Samsung Bioepis Co Ltd 1:24-CV-00005 ( D. DE )	STIPULATION of Dismissal without prejudice by Alexion Pharma International Operations Ltd., Alexion Pharmaceuticals, Inc.. (Silver, Daniel) (Entered: 08/30/2024)
06/24/24	Alexion Pharmaceuticals Inc v. Samsung Bioepis Co Ltd 1:24-CV-00005 ( D. DE )	ORDER of USCA as to 58 Notice of Appeal (Federal Circuit) filed by Alexion Pharmaceuticals, Inc., Alexion Pharma International Operations Ltd. Decision of USCA: Samsung is directed to respond to the motion no later than seven days from the date of entry of this order. Any reply in support of the motion is due no later than three days thereafter. (lnb) (Entered: 06/24/2024)
06/17/24	Alexion Pharmaceuticals Inc v. Samsung Bioepis Co Ltd 1:24-CV-00005 ( D. DE )	ORAL ORDER: The Court has reviewed Alexion's Emergency Motion for Injunction Pending Appeal (D.I. 60). The motion constitutes a motion for reconsideration with respect to the Court's prior injunction. "[T]o obtain reversal [of the denial of a preliminary injunction], the movant must show not only that one or more of the findings relied on by the district court was clearly erroneous, but also that denial of the injunction amounts to an abuse of the court's discretion upon reversal of erroneous findings." Reebok Int'l Ltd. v. J. Baker, Inc., 32 F.3d 1552, 1555 (Fed. Cir. 1994). The Court finds that Alexion has failed to show that the Court clearly erred and abused its discretion. Specifically, the Court finds that the well-reasoned IPR institution decision raises a substantial question of validity. Injunctions are an equitable remedy, and the Court will not grant an injunction on a patent likely to be invalid. See D.I. 57 at 2-5. With respect to the aHUS claim, the Court finds that it did not clearly err in finding that a person of ordinary skill in the art would "have known that SOLIRIS was clinically safe and possessed a reasonable likelihood of successfully treating aHUS by inhibiting the C5 pathway." D.I. 57 at 6. Alexion's arguments re-hash the arguments it has already made, and do not convince the Court that it has clearly erred or abused its discretion. Thus, the Court DENIES Alexion's Emergency Motion for Injunction Pending Appeal. Ordered by Judge Gregory B. Williams on 6/17/2024. (lnb) (Entered: 06/17/2024) ORAL ORDER: The Court has reviewed Alexion's Emergency Motion for Injunction Pending Appeal (D.I. 60). The motion constitutes a motion for reconsideration with respect to the Court's prior injunction. "[T]o obtain reversal [of the denial of a preliminary injunction], the movant must show not only that one or more of the findings relied on by the district court was clearly erroneous, but also that denial of the injunction amounts to an abuse of the court's discretion upon reversal of erroneous findings." Reebok Int'l Ltd. v. J. Baker, Inc., 32 F.3d 1552, 1555 (Fed. Cir. 1994). The Court finds that Alexion has failed to show that the Court clearly erred and abused its discretion. Specifically, the Court finds that the well-reasoned IPR institution decision raises a substantial question of validity. Injunctions are an equitable remedy, and the Court will not grant an injunction on a patent likely to be invalid. See D.I. 57 at 2-5. With respect to the aHUS claim, the Court finds that it did not clearly err in finding that a person of ordinary skill in the art would "have known that SOLIRIS was clinically safe and possessed a reasonable likelihood of successfully treating aHUS by inhibiting the C5 pathway." D.I. 57 at 6. Alexion's arguments re-hash the arguments it has already made, and do not convince the Court that it has clearly erred or abused its discretion. Thus, the Court DENIES Alexion's Emergency Motion for Injunction Pending Appeal. Ordered by Judge Gregory B. Williams on 6/17/2024. (lnb) (Entered: 06/17/2024)
06/14/24	Alexion Pharmaceuticals Inc v. Samsung Bioepis Co Ltd 1:24-CV-00005 ( D. DE )	REDACTED VERSION of 74 Declaration by Alexion Pharma International Operations Ltd., Alexion Pharmaceuticals, Inc.. (Zare, Maliheh) (Entered: 06/14/2024)
06/14/24	Alexion Pharmaceuticals Inc v. Samsung Bioepis Co Ltd 1:24-CV-00005 ( D. DE )	REDACTED VERSION of 73 Reply Brief, by Alexion Pharma International Operations Ltd., Alexion Pharmaceuticals, Inc.. (Zare, Maliheh) (Entered: 06/14/2024)
06/07/24	Alexion Pharmaceuticals Inc v. Samsung Bioepis Co Ltd 1:24-CV-00005 ( D. DE )	[SEALED] DECLARATION re 73 Reply Brief, of Andrew J. Cochran, Esq. by Alexion Pharma International Operations Ltd., Alexion Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-B, # 2 Certificate of Service)(Joyce, Alexandra) (Entered: 06/07/2024)
06/07/24	Alexion Pharmaceuticals Inc v. Samsung Bioepis Co Ltd 1:24-CV-00005 ( D. DE )	[SEALED] REPLY BRIEF re 60 MOTION Emergency Motion for Injunction Pending Appeal and Temporary Restraining Order Pending Resolution of this Motion filed by Alexion Pharma International Operations Ltd., Alexion Pharmaceuticals, Inc.. (Attachments: # 1 Certificate of Service)(Joyce, Alexandra) (Entered: 06/07/2024)
06/07/24	Alexion Pharmaceuticals Inc v. Samsung Bioepis Co Ltd 1:24-CV-00005 ( D. DE )	ORDER re 71 Unopposed MOTION to Seal Reply Brief filed by Alexion Pharmaceuticals, Inc., Alexion Pharma International Operations Ltd. Signed by Judge Gregory B. Williams on 6/7/2024. (lnb) (Entered: 06/07/2024)